Drug intelligence / Profile preview

GSK576389A

Development stage: Phase 3
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

GSK576389A is an influenza vaccine developed by GSK Biologicals. It has been studied in multiple Phase 2 clinical trials to evaluate its safety, reactogenicity, and immunogenicity, particularly in elderly adults aged 65 years and above. The vaccine has been tested with various formulations and in repeated vaccination scenarios across different influenza seasons.

Other names: thiomersal reduced FluAS25 adjuvanted vaccine

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on GSK576389A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK576389A.

Explore the full profile